

**ertapenem sodium infusion
(Invanz) Paediatric
Merck Sharpe & Dohme**

(No. 291/06)

Product Update

7 July 2006

The Scottish Medicines Consortium has completed its assessment of the above product and advises Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Ertapenem is accepted for restricted use within NHS Scotland for the treatment of intra-abdominal infections in children and adolescents.

Ertapenem should only be used second line for the treatment of the community acquired intra-abdominal infections resistant to the current conventional treatments and under the advice of local microbiologists or specialists in infectious diseases.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16 June 2006.

**Vice Chairman,
Scottish Medicines Consortium**